Investing

Brookline Capital Downgrades Outlook Therapeutics

Fintel reports that on August 30, 2023, Brookline Capital downgraded their outlook for Outlook Therapeutics (NASDAQ:OTLK) from Buy to Hold.

Analyst Price Forecast Suggests 2,342.15% Upside

As of August 31, 2023, the average one-year price target for Outlook Therapeutics is 6.56. The forecasts range from a low of 4.54 to a high of $10.50. The average price target represents an increase of 2,342.15% from its latest reported closing price of 0.27.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Outlook Therapeutics is 4MM, a decrease of 30.30%. The projected annual non-GAAP EPS is -0.27.

What is the Fund Sentiment?

There are 165 funds or institutions reporting positions in Outlook Therapeutics. This is an increase of 5 owner(s) or 3.12% in the last quarter. Average portfolio weight of all funds dedicated to OTLK is 0.01%, an increase of 26.29%. Total shares owned by institutions increased in the last three months by 7.21% to 31,135K shares.

What are Other Shareholders Doing?

VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 3,610K shares representing 1.39% ownership of the company. No change in the last quarter.

IWM – iShares Russell 2000 ETF holds 3,429K shares representing 1.32% ownership of the company. In it’s prior filing, the firm reported owning 2,925K shares, representing an increase of 14.70%. The firm increased its portfolio allocation in OTLK by 72.51% over the last quarter.

Geode Capital Management holds 2,721K shares representing 1.05% ownership of the company. In it’s prior filing, the firm reported owning 2,538K shares, representing an increase of 6.73%. The firm increased its portfolio allocation in OTLK by 54.88% over the last quarter.

LVW Advisors holds 1,734K shares representing 0.67% ownership of the company. No change in the last quarter.

VEXMX – Vanguard Extended Market Index Fund Investor Shares holds 1,449K shares representing 0.56% ownership of the company. In it’s prior filing, the firm reported owning 1,324K shares, representing an increase of 8.63%. The firm increased its portfolio allocation in OTLK by 66.66% over the last quarter.

Outlook Therapeutics Background Information
(This description is provided by the company.)

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD.

This article originally appeared on Fintel

Sponsored: Tips for Investing

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.